The in-situ hybridization (ISH) market is expected to experience steady growth in the coming years, driven by factors such as increasing prevalence of cancer and genetic disorders, growing demand for personalized medicine, and rising investments in research and development activities. The fluorescence in-situ hybridization (FISH) segment is projected to dominate the market due to its high sensitivity and specificity, and its ability to provide accurate results. The academic and research institutes end-user segment is expected to account for the largest share of the market, followed by the diagnostic laboratories segment. North America is anticipated to hold the largest market share due to the presence of advanced healthcare infrastructure, increasing investments in R&D, and high adoption rate of advanced technologies. However, the market may face challenges such as high costs of instruments and reagents, and lack of awareness about ISH techniques among healthcare professionals.
Key players operating in the global In-Situ Hybridization Market include Abbott Laboratories, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Merck KGaA, PerkinElmer, Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories, Inc., Advanced Cell Diagnostics, Inc., and Bio SB Inc.
Prominent Companies in the In-Situ hybridization Industry:
1. Abbott Laboratories, Inc.
Abbott Laboratories, Inc. is an American multinational healthcare company that was founded in 1888 and is headquartered in Abbott Park, Illinois. The company operates in more than 160 countries worldwide, with a focus on the development and manufacture of medical devices, diagnostic products, and nutritional products. In May 2022, Abbott announced the launch of its Alinity™ m molecular diagnostic system, which enables fast and accurate detection of infectious diseases, including COVID-19.
2. Agilent Technologies, Inc.
Agilent Technologies, Inc. is an American analytical laboratory instrumentation and software company that was founded in 1999 and is headquartered in Santa Clara, California. The company operates in more than 50 countries worldwide and provides analytical solutions for life sciences, diagnostics, and applied chemical markets. In February 2022, Agilent announced the launch of its SureFISH probe panel for in-situ hybridization, which enables researchers to detect multiple genes in a single assay, thus saving time and increasing efficiency.
3. Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc. is an American company that provides scientific research products, services, and software solutions. The company was founded in 2006 and is headquartered in Waltham, Massachusetts. Thermo Fisher Scientific operates in more than 50 countries worldwide and offers products and services for life sciences, pharmaceuticals, and biotechnology industries. In January 2022, the company announced the launch of its new in-situ hybridization RNA assay, which enables researchers to visualize RNA expression patterns at a single-cell level.
4. F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that was founded in 1896 and is headquartered in Basel, Switzerland. The company operates in more than 100 countries worldwide and specializes in the research, development, and manufacturing of pharmaceuticals and diagnostics solutions. In October 2022, Roche announced the launch of its Ventana VENTANA ROS1 (SP384) companion diagnostic assay for in-situ hybridization, which enables the identification of patients with ROS1 fusion-positive non-small cell lung cancer.
5. Merck KGaA
Merck KGaA, also known as EMD Group, is a German multinational pharmaceutical, chemical, and life sciences company that was founded in 1668 and is headquartered in Darmstadt, Germany. The company operates in more than 60 countries worldwide and specializes in the development and production of pharmaceuticals, biotechnology products, and performance materials. In April 2023, Merck announced the launch of its new RNA-FISH assay, which enables the detection of RNA in tissue samples with high specificity and sensitivity.
6. PerkinElmer, Inc.
PerkinElmer, Inc. is an American company that provides analytical instruments, software, and services for the life sciences, diagnostics, and environmental markets. The company was founded in 1937 and is headquartered in Waltham, Massachusetts. PerkinElmer operates in more than 190 countries worldwide and offers a range of solutions for genomics, proteomics, and in-situ hybridization. In January 2022, the company announced the launch of its new in-situ hybridization probes, which provide high signal intensity and low background noise for increased sensitivity and accuracy.
7. Oxford Gene Technology
Oxford Gene Technology is a British company that specializes in the development and manufacture of molecular genetics research products, including microarrays and in-situ hybridization probes. The company was founded in 1995 and is headquartered in Begbroke, Oxfordshire, UK. Oxford Gene Technology operates in more than 50 countries worldwide and provides solutions for cytogenetics, cancer research, and rare disease diagnosis.
Definition- In-situ hybridization (ISH) is a molecular biology technique used to detect and locate specific DNA or RNA sequences within cells or tissues, providing information about gene expression, mutations, and chromosomal abnormalities.
